Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

The drug facts box: providing consumers with simple tabular data on drug benefit and harm.

Schwartz LM, Woloshin S, Welch HG.

Med Decis Making. 2007 Sep-Oct;27(5):655-62. Epub 2007 Sep 14.

PMID:
17873258
2.

The effectiveness of a primer to help people understand risk: two randomized trials in distinct populations.

Woloshin S, Schwartz LM, Welch HG.

Ann Intern Med. 2007 Feb 20;146(4):256-65.

PMID:
17310049
3.

Using a drug facts box to communicate drug benefits and harms: two randomized trials.

Schwartz LM, Woloshin S, Welch HG.

Ann Intern Med. 2009 Apr 21;150(8):516-27. Epub 2009 Feb 16.

PMID:
19221371
4.

Comprehension of information in three direct-to-consumer television prescription drug advertisements among adults with limited literacy.

Kaphingst KA, Rudd RE, Dejong W, Daltroy LH.

J Health Commun. 2005 Oct-Nov;10(7):609-19.

PMID:
16278198
5.

Pharmaceutical advertising as a consumer empowerment device.

Rubin PH.

J Biolaw Bus. 2001;4(4):59-65.

PMID:
12751498
6.

Television advertisement format and the provision of risk information about prescription drug products.

Glinert LH, Schommer JC.

Res Social Adm Pharm. 2005 Jun;1(2):185-210.

PMID:
17138474
7.

The value of benefit data in direct-to-consumer drug ads.

Woloshin S, Schwartz LM, Welch HG.

Health Aff (Millwood). 2004 Jan-Jun;Suppl Web Exclusives:W4-234-45.

PMID:
15452006
8.

Literacy demands of product information intended to supplement television direct-to-consumer prescription drug advertisements.

Kaphingst KA, Rudd RE, DeJong W, Daltroy LH.

Patient Educ Couns. 2004 Nov;55(2):293-300.

PMID:
15530767
10.

Randomized trial of risk information formats in direct-to-consumer prescription drug advertisements.

Aikin KJ, O'Donoghue AC, Swasy JL, Sullivan HW.

Med Decis Making. 2011 Nov-Dec;31(6):E23-33. doi: 10.1177/0272989X11413289. Epub 2011 Jun 20.

PMID:
21690303
11.

Consumers' preferences for the communication of risk information in drug advertising.

Davis JJ.

Health Aff (Millwood). 2007 May-Jun;26(3):863-70.

PMID:
17485767
12.

Communicating data about the benefits and harms of treatment: a randomized trial.

Woloshin S, Schwartz LM.

Ann Intern Med. 2011 Jul 19;155(2):87-96. doi: 10.7326/0003-4819-155-2-201107190-00004.

PMID:
21768582
13.

Message strategies in direct-to-consumer pharmaceutical advertising: a content analysis using Taylor's six-segment message strategy wheel.

Tsai WH, Lancaster AR.

Health Mark Q. 2012;29(3):239-55. doi: 10.1080/07359683.2012.705708.

PMID:
22905945
14.

Presenting efficacy information in direct-to-consumer prescription drug advertisements.

O'Donoghue AC, Sullivan HW, Aikin KJ, Chowdhury D, Moultrie RR, Rupert DJ.

Patient Educ Couns. 2014 May;95(2):271-80. doi: 10.1016/j.pec.2013.12.010. Epub 2013 Dec 25.

PMID:
24581929
15.

Inappropriate dosage instructions in package inserts.

Fuchs J, Hippius M.

Patient Educ Couns. 2007 Jul;67(1-2):157-68. Epub 2007 Apr 23.

PMID:
17451909
16.

The attitudes of consumers toward direct advertising of prescription drugs.

Morris LA, Brinberg D, Klimberg R, Rivera C, Millstein LG.

Public Health Rep. 1986 Jan-Feb;101(1):82-9.

17.
18.

Consumer attitudes about advertisements for medicinal drugs.

Morris LA, Brinberg D, Klimberg R, Millstein L, Rivera C.

Soc Sci Med. 1986;22(6):629-38.

PMID:
3715502
19.

Profiles of tamoxifen-related side effects by race and smoking status in women with breast cancer.

Zhan M, Flaws JA, Gallicchio L, Tkaczuk K, Lewis LM, Royak-Schaler R.

Cancer Detect Prev. 2007;31(5):384-90. Epub 2007 Nov 26.

PMID:
18023540
20.

Financial disclosure and clinical research: what is important to participants?

Hutchinson A, Rubinfeld AR.

Med J Aust. 2008 Aug 18;189(4):207-9.

PMID:
18707564

Supplemental Content

Support Center